MCID: LYM019
MIFTS: 56

Lymphosarcoma

Categories: Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymphosarcoma

Summaries for Lymphosarcoma

Disease Ontology : 12 A sarcoma that has_material_basis in lymphatic tissue.

MalaCards based summary : Lymphosarcoma, also known as malignant lymphoma, is related to mantle cell lymphoma and testicular lymphoma. An important gene associated with Lymphosarcoma is MIR20A (MicroRNA 20a), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and NF-kappaB Signaling. The drugs Adcetris and Arranon have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 76 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for Lymphosarcoma

Diseases related to Lymphosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 453)
# Related Disease Score Top Affiliating Genes
1 mantle cell lymphoma 32.1 BCL6 CD5 PTPRC
2 testicular lymphoma 32.0 BCL6 PTPRC
3 breast lymphoma 31.5 BCL6 CD5 CD79A SMUG1
4 diffuse large b-cell lymphoma 31.4 BCL6 CD5 CD79A
5 b-cell lymphomas 29.9 BCL6 CD5 MIR20A
6 bone lymphoma 29.8 BCL6 CD22 SMUG1
7 prostate lymphoma 29.7 CD5 SMUG1
8 bladder lymphoma 29.7 CD5 CD79A
9 leukemia, chronic lymphocytic 29.6 BCL6 CD5 MIR19A MIR92A1 PTPRC
10 hodgkin's lymphoma, lymphocytic-histiocytic predominance 29.6 BCL6 PTPRC
11 rectosigmoid junction neoplasm 29.6 CTSL SMUG1
12 marginal zone b-cell lymphoma 29.5 BCL6 CD5 CD79A
13 lymphoblastic lymphoma 29.4 BCL6 CD5 PTPRC
14 parotitis 29.4 CD79A G6PD H6PD
15 lymphoma, mucosa-associated lymphoid type 29.1 BCL6 CD5 CD79A SMUG1
16 lymphoma, hodgkin, classic 28.7 BCL6 CD22 CD5 CD79A MIR20A PTPRC
17 mediastinal malignant lymphoma 12.2
18 lymphoproliferative syndrome, x-linked, 1 11.6
19 lymphoproliferative syndrome 2 11.2
20 lymphoma, small cleaved-cell, diffuse 11.1
21 lymphoproliferative syndrome, x-linked, 2 11.0
22 intraocular lymphoma 11.0
23 waldenstrom macroglobulinemia 11.0
24 leukemia 10.6
25 sarcoma 10.4
26 reticulum cell sarcoma 10.4
27 lymphoma 10.3
28 hepatitis 10.3
29 leukemia, acute lymphoblastic 3 10.2
30 lymphocytic leukemia 10.2
31 heart lymphoma 10.2 BCL6 PTPRC
32 hepatitis c 10.2
33 meningococcal infection 10.2 G6PD GSR
34 brain sarcoma 10.2 PTPRC SMUG1
35 trachea adenoid cystic carcinoma 10.2 CTSL SMUG1
36 reticulosarcoma 10.1
37 glucosephosphate dehydrogenase deficiency 10.1 G6PD H6PD
38 mandibular cancer 10.1 CTSL SMUG1
39 root caries 10.1 CD79A SMARCA4
40 hodgkin's lymphoma, lymphocytic depletion 10.1 CD79A PTPRC
41 panophthalmitis 10.1 CD79A CTSL
42 plasmablastic lymphoma 10.1 BCL6 PTPRC
43 testicular torsion 10.1 CD79A GSR
44 arthritis 10.1
45 leukemia, chronic lymphocytic 2 10.1
46 leukemia, b-cell, chronic 10.1
47 rheumatoid arthritis 10.1
48 hepatitis c virus 10.1
49 testis seminoma 10.1 DNMT3A PTPRC SMUG1
50 hepatitis b 10.1

Graphical network of the top 20 diseases related to Lymphosarcoma:



Diseases related to Lymphosarcoma

Symptoms & Phenotypes for Lymphosarcoma

GenomeRNAi Phenotypes related to Lymphosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 BCL6 CD22 CD5 CD79A CTSL DNMT3A

MGI Mouse Phenotypes related to Lymphosarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.91 BCL6 CD22 CD79A DNMT3A G6PD NR3C1
2 hematopoietic system MP:0005397 9.85 BCL6 CD22 CD5 CD79A DNMT3A G6PD
3 immune system MP:0005387 9.61 BCL6 CD22 CD5 CD79A DNMT3A NR3C1
4 normal MP:0002873 9.17 BCL6 CD5 CD79A GSR NR3C1 PTPRC

Drugs & Therapeutics for Lymphosarcoma

FDA approved drugs:

(show all 27)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
3
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
4
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
5
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
6
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
7
Elitek 18 49 RASBURICASE sanofi-aventis October 2009
8
Elliotts B Solution 18 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
9
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
10
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
11
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
12
Istodax 18 49 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
13
Kyprolis 18 49 CARFILZOMIB Onyx Pharmaceuticals July 2012
14
Mozobil 18 49 PLERIXAFOR Genzyme December 2008
15
Neumega 18 OPRELVEKIN Genetics Institute November 1997
16
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
17
Rituxan 18 49 RITUXIMAB Biogen IDEC, Genentech November 1997
18
Targretin 18 49 bexarotene VALEANT LUXEMBOURG 12/29/1999
19
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
20
UVADEX 18 METHOXSALEN Therakos February 1999
21
Valchlor 18 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013
22
Velcade 18 49 BORTEZOMIB Millennium Pharmaceuticals May 2003
23
Xalkori 18 49 CRIZOTINIB Pfizer August of 2011
24
Zevalin 18 49 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
25
Zydelig 18 49 IDELALISIB Gilead July 2014
26
Zykadia 18 49 CERITINIB Novartis April 2014
27
Alecensa 18 ALECTINIB HYDROCHLORIDE Roche December 2015

Drugs for Lymphosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 990)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
2
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 241903 13342
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
4
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
7
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
8
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
9
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-22-7, 2068-78-2 5978
10
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
11
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
12
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
13
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
14
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
15
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
16
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 95058-81-4 60750
17
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
20
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Phase 1 13422-51-0 11953898 44475014
21
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6 23925
22
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 13422-55-4
23
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
24
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
25
Entecavir Approved, Investigational Phase 4,Phase 2,Not Applicable 142217-69-4 153941
26
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 172673-20-0 219090
27
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 170729-80-3 6918365 151165
28
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
29
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
30
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
31
Tropisetron Approved, Investigational Phase 4,Not Applicable 89565-68-4, 105826-92-4 5595
32
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
33
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
34
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
35
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
36
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
37
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29767-20-2 34698
38
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
39
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 65271-80-9 4212
40
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
41
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 130167-69-0
42
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59917-39-4, 53643-48-4 40839
43
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4291-63-8 20279
44
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
45
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 173146-27-5
46
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 153559-49-0 82146
47
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
48
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
49
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
50
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 159351-69-6 6442177

Interventional clinical trials:

(show top 50) (show all 6814)
# Name Status NCT ID Phase Drugs
1 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Unknown status NCT02585947 Phase 4 Tenofovir
2 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
3 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
4 PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
5 Treatment of Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
6 Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
7 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
8 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
9 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
10 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
11 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
12 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
13 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
14 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
15 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
16 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
17 A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02576327 Phase 4 Tropisetron;Dexamethasone;Aprepitant
18 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
19 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
20 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
21 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Unknown status NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
22 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
23 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
24 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
25 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
26 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
27 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
28 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
29 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
30 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
31 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
32 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
33 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
34 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
35 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
36 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
37 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
38 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
39 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
40 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
41 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
42 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
43 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
44 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
45 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
46 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
47 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab
48 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
49 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
50 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4 Valsartan

Search NIH Clinical Center for Lymphosarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Lymphosarcoma

Anatomical Context for Lymphosarcoma

MalaCards organs/tissues related to Lymphosarcoma:

41
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Breast, Thyroid

Publications for Lymphosarcoma

Articles related to Lymphosarcoma:

(show top 50) (show all 2475)
# Title Authors Year
1
Methotrexate (MTX)-associated malignant lymphoma of the bilateral breast: imaging features in comparison to other nipple-areolar tumors. ( 30340074 )
2019
2
Secondary Syphilis with Tonsillar and Cervical Lymphadenopathy and a Pulmonary Lesion Mimicking Malignant Lymphoma. ( 29502129 )
2018
3
Myeloid Sarcoma Presented as Generalized Lymphadenopathy: Mimicking Malignant Lymphoma. ( 29398826 )
2018
4
A case of duodenal malignant lymphoma presenting as acute pancreatitis: systemic lupus erythematosus and immunosuppressive therapy as risk factors. ( 29546569 )
2018
5
Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan. ( 29502313 )
2018
6
Low level of serum HDL-cholesterol with increased sIL-2R predicts a poor clinical outcome for patients with malignant lymphoma and adult T-cell leukemia-lymphoma. ( 29459344 )
2018
7
Abdominal aortic aneurysm with periaortic malignant lymphoma differentiated from aneurysmal rupture by clinical presentation and magnetic resonance imaging. ( 29942890 )
2018
8
Risk of malignant lymphoma in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs and methotrexate
. ( 30526810 )
2018
9
Invasive tracheobronchial aspergillosis developed during radioimmunotherapy for malignant lymphoma. ( 29636952 )
2018
10
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. ( 28368466 )
2018
11
Fulminant adenovirus hepatitis with adenovirus-associated esophagitis complicating malignant lymphoma. ( 29350488 )
2018
12
Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17. ( 30174428 )
2018
13
Malignant Lymphoma of the Ileum Presenting as Ileocecal Intussusception. ( 29119526 )
2018
14
Cardiac involvement of malignant lymphoma presenting intra-ventricular-wall nodules. ( 30506180 )
2018
15
An autopsy case of progressive multifocal leukoencephalopathy after rituximab therapy for malignant lymphoma. ( 30511425 )
2018
16
Malignant Lymphoma of the Ovary: A Diagnostic Pitfall of Intraoperative Consultation. ( 30516619 )
2018
17
Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification. ( 30311404 )
2018
18
A Case of Primary Malignant Lymphoma of the Prostate Gland Presenting as Right Lower Back Pain and Dysuria. ( 30259894 )
2018
19
Home-Based Yoga Program for the Patients Suffering from Malignant Lymphoma during Chemotherapy: A Feasibility Study. ( 30233121 )
2018
20
Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging. ( 30248447 )
2018
21
Lymphadenopathy with coexisting normal architecture in malignant lymphoma. ( 30191510 )
2018
22
Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ( 30210349 )
2018
23
A Rare Case of Rush Progression of Purulent Pericarditis by Escherichia coli in a Patient with Malignant Lymphoma. ( 29628470 )
2018
24
Bacteremia Possibly Caused by Helicobacter cinaedi and Associated with Painful Erythema in Rheumatoid Arthritis with Malignant Lymphoma. ( 30146580 )
2018
25
Diagnostic accuracy and interobserver agreement of contrast-enhanced ultrasound in the evaluation of residual lesions after treatment for malignant lymphoma and testicular cancer: a retrospective pilot study in 52 patients. ( 29486623 )
2018
26
Diffusion-Weighted Imaging Shows a False-Negative Finding for Bone Marrow Involvement on 18F-FDG PET/MRI in a Patient With Malignant Lymphoma After Blood Transfusion. ( 29561522 )
2018
27
Malignant lymphoma with middle ear involvement in a Sprague-Dawley rat. ( 29566591 )
2018
28
Peripheral Blood Monocyte Count is a Predictor of Successful Peripheral Blood Stem Cell Harvest After Chemo-Mobilization in Patients with Malignant Lymphoma. ( 29622882 )
2018
29
Improving lymph node characterization in staging malignant lymphoma using first-order ADC texture analysis from whole-body diffusion-weighted MRI. ( 29656584 )
2018
30
Malignant lymphoma in the HIV-positive patient. ( 29663523 )
2018
31
Malignant lymphoma of the uterine cervix presumptively diagnosed by Pap smear: A case report. ( 29725409 )
2018
32
A rare case of a spontaneously ruptured secondary hepatic malignant lymphoma. ( 29725882 )
2018
33
Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma. ( 29754771 )
2018
34
Lentivirus-mediated down-regulation of CK2α inhibits proliferation and induces apoptosis of malignant lymphoma and leukemia cells. ( 29772186 )
2018
35
Successful Use of a Multidisciplinary Approach to Treat a Perforated Duodenal Malignant Lymphoma in an Elderly Patient. ( 29808137 )
2018
36
Impact of Franseen needle on rapid onsite evaluation and histological examination following endoscopic ultrasonography-guided tissue acquisition in patients with splenic malignant lymphoma. ( 29858116 )
2018
37
Dual-energy CT in patients with abdominal malignant lymphoma: impact of noise-optimised virtual monoenergetic imaging on objective and subjective image quality. ( 29884524 )
2018
38
ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients. ( 29924296 )
2018
39
Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-Hodgkin Malignant Lymphoma Patients Who Underwent Stem Cell Transplantation. ( 29942400 )
2018
40
Baseline Global Longitudinal Strain as a Predictor of Left Ventricular Dysfunction and Hospitalization for Heart Failure of Patients With Malignant Lymphoma After Anthracycline Therapy. ( 29984789 )
2018
41
Incidence Rate, Subtype Frequency, and Occurrence Site of Malignant Lymphoma in the Gastrointestinal Tract: Population-Based Analysis in Miyagi, Japan. ( 29998914 )
2018
42
Dual-energy CT-based iodine quantification to differentiate abdominal malignant lymphoma from lymph node metastasis. ( 30017291 )
2018
43
Establishment of a detection assay for DNA endonuclease activity and its application in the screening and prognosis of malignant lymphoma. ( 30064372 )
2018
44
Three cases of spontaneous splenic rupture in malignant lymphoma. ( 30144001 )
2018
45
Epidemiologic characteristics of malignant lymphoma in Hubei, China: A single-center 5-year retrospective study. ( 30170444 )
2018
46
A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy. ( 28823027 )
2018
47
Useful laboratory markers for the diagnosis of bone marrow involvement by malignant lymphoma. ( 28876549 )
2018
48
Application of DWIBS in malignant lymphoma: correlation between ADC values and Ki-67 index. ( 29143105 )
2018
49
Malignant lymphoma arising in cardiac myxoma, presenting with peripheral arterial emboli. ( 29153872 )
2018
50
ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. ( 29194473 )
2018

Variations for Lymphosarcoma

Expression for Lymphosarcoma

Search GEO for disease gene expression data for Lymphosarcoma.

Pathways for Lymphosarcoma

GO Terms for Lymphosarcoma

Cellular components related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD5 CD79A GSR PTPRC

Biological processes related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pentose-phosphate shunt GO:0006098 9.26 G6PD H6PD
2 NADP metabolic process GO:0006739 9.16 G6PD H6PD
3 B cell differentiation GO:0030183 9.13 BCL6 CD79A PTPRC
4 negative regulation of sprouting angiogenesis GO:1903671 8.8 MIR19A MIR20A MIR92A1

Molecular functions related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADP binding GO:0050661 9.13 G6PD GSR H6PD
2 glucose-6-phosphate dehydrogenase activity GO:0004345 8.62 G6PD H6PD

Sources for Lymphosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....